Schwabe takes stake in NeuroNation to combine pharma with digital brain health
What's the deal? Germany's Schwabe Group has acquired a strategic stake in Synaptikon GmbH, the Berlin-based company behind the NeuroNation brain training app and the NeuroNation MED digital health application. The deal pairs Schwabe's pharmaceutical expertise — notably its Tebonin ginkgo extract for cognitive health — with Synaptikon's digital therapy platform.
NeuroNation MED is a prescription digital health application (known in Germany as a DiGA) that targets people with acquired or neurodegenerative mild cognitive impairments. It is currently used by around 25% of patients diagnosed with mild cognitive disorder in Germany. The broader NeuroNation brain training app reaches 30 million users across 150 countries in 14 languages.
Why now? Germany has been a pioneer in prescription digital therapeutics since introducing its DiGA framework in 2020, and NeuroNation was the first app-on-prescription in the country. Research consensus is increasingly clear that preventing and treating neurodegenerative diseases requires a holistic approach combining pharmaceutical and lifestyle interventions.
"We are convinced that the combination of medicine and digital solutions creates strong synergy for patients," Schwabe and Synaptikon's founders said in a joint statement. Both companies aim to help people maintain cognitive health through scientifically validated products.
What could go wrong? Merging a 150-year-old pharmaceutical company's culture with a digital health startup is never straightforward. Scaling a German prescription app internationally also means navigating different regulatory regimes for digital therapeutics — frameworks that remain patchy or non-existent in many markets.
The financial terms of the deal were not disclosed, making it hard to gauge the level of commitment or the resources Synaptikon will gain.
The signal: Traditional pharma companies are increasingly buying into digital health rather than building it themselves. Schwabe's move reflects a broader trend of established healthcare players seeking to complement physical products with digital companions — especially in areas like cognitive health and mental wellbeing, where patient engagement between doctor visits matters most.
The deal also underscores Germany's outsized role in digital therapeutics. Its DiGA fast-track pathway has created a unique market where startups can prove clinical value and get reimbursed by statutory health insurers, giving them a commercial foothold that digital health companies in other countries struggle to find.
Read more: firmenpresse.de
